New preprint from Mara Sherman Lab Memorial Sloan Kettering Cancer Center Stromal KITL/SCF promotes pancreas tissue homeostasis and restrains tumor progression biorxiv.org/content/10.110… This study examines what factor(s) in the normal pancreatic mesenchyme might be lost in the process of multistep

Components of normal tissue architecture maintain structure (+ fxn) & serve as barriers to tumor progression…but how? We report a 🧩 in our new preprint. Congrats to 1st author M. Kathrina Oñate & thx to collabs Memorial Sloan Kettering Cancer Center OHSU Knight Cancer Institute Stanford Medicine! 1/ biorxiv.org/content/10.110…

Glycosphingolipid synthesis mediates immune evasion in KRAS-driven cancer nature.com/articles/s4158… Kivanc Birsoy in nature “Blocking sphingolipid production in cancer cells enhances the anti-proliferative effects of natural killer and CD8+ T cells partly via interferon-γ (IFNγ)

From Luciane T Kagohara 🇧🇷🧬👩🏻‍🔬👩🏻‍💻 Ashley Kiemen Denis Wirtz & colleagues Johns Hopkins Kimmel Cancer Center PanIN and CAF transitions in pancreatic carcinogenesis revealed with spatial data integration sciencedirect.com/science/articl… Spatial transcriptomics of archival #PancreaticCancer precursor lesions, with validation

New preprint from Wantong Yao Haoqiang Ying Scott Kopetz MD Anderson Cancer Center Therapeutic targeting of Syndecan-1 axis overcomes acquired resistance to KRAS-targeted therapy in gastrointestinal cancers biorxiv.org/content/10.110… In preclinical models of #PancreaticCancer & #ColorectalCancer,

Wonderful new study on #macrophages in the glioma #microenvironment ⬇️ Macrophage-mediated myelin recycling fuels brain cancer malignancy Congratulations to Daan J. Kloosterman, #JohannaErbani, Leila Akkari & all authors 🤩- so happy to see this out! 👏👏👏 cell.com/cell/fulltext/…

Mammalian SWI/SNF complex activity regulates POU2F3 and constitutes a targetable dependency in small cell lung cancer dlvr.it/TBr41J

Aging in humans in non-linear. Incredible Nature Aging study by Michael Snyder, PhD. nature.com/articles/s4358… Coincidentally the 1st wave of deregulation occurs at ~44 years, which also happens to be the median age of receiving the 1st R01 for many investigators. Grant writing 👉🏽 Aging

The Cancer-Immunity Cycle By Ira Mellman & colleagues in Immunity 2013: cell.com/immunity/fullt… 2023 update: cell.com/immunity/fullt… (L) 2013 (R) 2023 The underlying concepts have been the capstone for a lot of modern day cancer immunotherapy research.

Preprint from Reza Kalhor (in collaboration with Dr. Elana J Fertig Hani Goodarzi et al): Identifying a gene signature of metastatic potential by linking pre-metastatic state to ultimate metastatic fate biorxiv.org/content/10.110… Interesting study that uses barcoded single cell isolates of

Online Now: The KRAS mutational spectrum and its clinical implications in pancreatic cancer dlvr.it/TCXSrH

Glad to share our latest study published in Cell Reports Medicine. We developed transgenic mouse models with wild-type KRAS, showing unique adenosquamous phenotypes of pancreatic cancer. Many thanks to our collaborators Anirban Maitra Huamin Wang, MD, PhD MD Anderson Cancer Center cell.com/cell-reports-m…

Fibrotic response to anti-CSF-1R therapy potentiates glioblastoma recurrence dlvr.it/TDCJJC

New paper in Gut Journal from Fredrik Thege & colleagues MD Anderson Cancer Center, just in time for #AACRPan24: Metabolic reprogramming by mutant GNAS creates an actionable dependency in intraductal papillary mucinous neoplasms of the pancreas gut.bmj.com/content/early/…

All the KRAS inhibitor compounds Andrew Aguirre could fit on a slide! #AACRPan24

I found these three summary slides from Channing Der on (left) diverse mechanisms of action for KRAS inhibitors & (center, right) acquired genetic mechanisms of resistance to KRASi really useful. #AACRPan24

New perpsective in Gastroenterology from talented postdoctoral fellow Dr. LaNisha Patterson MD Anderson Cancer Center (LaNisha Patterson, MS, PhD) #PancreaticCancer–induced metabolic dysregulation syndrome: clinical profile, proposed mechanisms, and unanswered questions gastrojournal.org/article/S0016-…

The latest MD Anderson research includes potential therapeutic targets for developing tailored treatments for patients with non-mutant KRAS pancreatic cancer, as well as a recap from #ESMO24: brnw.ch/21wMSJr ESMO - Eur. Oncology Yang Chen #CancerResearch #EndCancer

The Boehringer Ingelheim KRAS degrader in Science Magazine science.org/doi/10.1126/sc… Perspective from Adrienne Cox & Channing Der science.org/doi/10.1126/sc…

#OpenAccess viewpoint in Journal of Clinical Investigation from Bhardwaj Lab The Tisch Cancer Institute Checkpoint therapy in cancer treatment: progress, challenges, and future directions jci.org/articles/view/…